EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adenosine A 3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

Maria Beatrice Morelli iD, Andrea Spinaci, Cui Chang, Rosaria Volpini, Catia Lambertucci, Matteo Landriscina, Vincenza Conteduca, Consuelo Amantini, Cristina Aguzzi, Laura Zeppa, Martina Giangrossi, Laura Soverchia und 4 weitere

FEBS Open Bio · 2025-07 · 15 (7) · 1159-1175

DOI: 10.1002/2211-5463.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 03.04.2025. Verfasst von Maria Beatrice Morelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Medicine Unit, School of Pharmacy, University of Camerino, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antineoplastic Agents, Receptor, Adenosine A3, Adenosine A3 Receptor Antagonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is one of the most common cancers in men, and for patients with PCa that cannot be surgically resected or treated, androgen suppression therapy often results in significant adverse effects. Recent studies have shown that A3 adenosine receptors (A 3 ARs) are overexpressed in prostate cancer (PCa), and several A 3 AR agonists and antagonists have been investigated as potential anticancer drugs. In this study, we investigated the potential therapeutic effects of the A 3 AR antagonists AR 292 and AR 357 in human PCa cell lines. LNCaP, DU‐145, and PC3 cell lines were treated with AR 292 and AR 357 compounds, and their cytotoxic effects were determined using viability assays, flow cytometry, and western blotting. Moreover, the drug transporter gene profile was evaluated using RT‐PCR in untreated and A 3 AR antagonist‐treated PCa cells. Both AR 292 and AR 357 showed antiproliferative effects with significant cell cycle arrest and induced DNA damage leading to cell death. AR 292 and especially AR 357 modulated the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response. Ferroptosis was induced in DU‐145 cells treated with both compounds as well as in PC3 cells treated with AR 357. However, the treatment of PC3 cells with AR 292 and the treatment of LNCaP cells with both AR 292 and AR 357 resulted in necrotic cell death. In conclusion, our study showed that A 3 AR ligands exert anticancer effects via different mechanisms on PCa cell lines through the activation of multiple molecular pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAntineoplastic AgentsReceptor, Adenosine A3Adenosine A3 Receptor AntagonistsHumansMaleCell Line, TumorCell ProliferationCell SurvivalApoptosis

Stichwörter der Autor:innen

PC3 cell lineadenosineadenosine receptor antagonistschemotherapyprostate cancer

Substanzen

Antineoplastic AgentsReceptor, Adenosine A3Adenosine A3 Receptor Antagonists

Autor:innen und Institutionen

  • Experimental Medicine Unit, School of Pharmacy, University of Camerino, Italy.
  • Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Italy.
  • Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences - Ospedali Riuniti, University of Foggia, Foggia, Italy.
  • School of Bioscience and Veterinary Medicine, University of Camerino, Italy.
  • Oncology Unit, Macerata Hospital, Macerata, Italy.

ORCID-Profile: Maria Beatrice Morelli, Carlo Polidori

Zitieren

APA

Morelli, M. B., Spinaci, A., Chang, C., Volpini, R., Lambertucci, C., Landriscina, M., Conteduca, V., Amantini, C., Aguzzi, C., Zeppa, L., Giangrossi, M., Soverchia, L., Santoni, M., Nabissi, M., Santoni, G., & Polidori, C. (2025). Adenosine A 3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study. FEBS Open Bio, 15(7), 1159-1175. https://doi.org/10.1002/2211-5463.70024

Vancouver

Morelli MB, Spinaci A, Chang C, Volpini R, Lambertucci C, Landriscina M, et al. Adenosine A 3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study. FEBS Open Bio. 2025;15(7):1159-1175. doi:10.1002/2211-5463.70024

BibTeX
@article{Morelli2025,
  author = {Morelli, Maria Beatrice and Spinaci, Andrea and Chang, Cui and Volpini, Rosaria and Lambertucci, Catia and Landriscina, Matteo and Conteduca, Vincenza and Amantini, Consuelo and Aguzzi, Cristina and Zeppa, Laura and Giangrossi, Martina and Soverchia, Laura and Santoni, Matteo and Nabissi, Massimo and Santoni, Giorgio and Polidori, Carlo},
  title = {Adenosine A 3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study},
  journal = {FEBS Open Bio},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {1159--1175},
  doi = {10.1002/2211-5463.70024}
}
Kostenlos starten →